Enimmune corporation Profit Margin

Enimmune corporation (6564.TWO) currently reports a profit margin of -333.26% as of June 2026. That compares with -227.31% in the prior-year period — down 46.6% year over year. That is below the Healthcare sector average of 10.58%. Use the charts on this page to explore Enimmune corporation's profit margin history and peer comparisons.

Enimmune corporation's profit margin decreased from -227.31% to -333.26% — a 46.6% year-over-year decrease (period ending June 2026). Watching multi-year history on the chart below helps separate one-off swings from a lasting trend.

Enimmune corporation's profit margin of -333.26% is lower than the Healthcare sector average of 10.58%. That is roughly 3249.7% below the sector mean. A reading lower peers can reflect different growth expectations, capital structure, or profitability — so it is worth checking the peer comparison chart before drawing conclusions.

There is no universal 'good' profit margin, but Enimmune corporation's current -333.26% should be judged against Healthcare norms (sector average: 10.58%) and against 6564.TWO's own history. Strong, stable readings often indicate durable competitive advantage; volatile or declining ones deserve a closer look at margins and capital efficiency.

Start with the current profit margin of -333.26%, then check the historical chart for trend and the peer comparison chart for relative positioning. The Healthcare average is 10.58%. From there, open related valuation or income-statement pages for Enimmune corporation, and consider following 6564.TWO for alerts when major investors trade the stock.